TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29137628
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (NS group) pre-injection 4 mL/kg isotonic saline
Study: 26637580
Drug: Long-term low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Long-term low-dose azithromycin (250 mg daily for 3 months) plus standard conventional treatment (fluticasone nasal spray plus normal saline solution irrigation)
Study: 26637580
Drug: Standard conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conventional treatment (fluticasone nasal spray plus normal saline solution irrigation)
Study: 24924416
Drug: Fulvestrant (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (500 mg IM days 1, 15, 29, then monthly) plus Vandetanib (100 mg PO OD)
Study: 24924416
Drug: Fulvestrant (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (500 mg IM days 1, 15, 29, then monthly) plus Placebo
Study: 19463034
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy (10-week project with ten one-hour weekly sessions including song singing, song writing, and improvisation)
Study: 23639952
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy
Study: 16131696
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg caffeine . kg(‐1) . d(‐1) (C3)
Study: 16131696
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg caffeine . kg(‐1) . d(‐1) (C6)
Study: 16131696
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg caffeine . kg(‐1) . d(‐1) (C0; placebo)
Study: 9987086
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD) 0.6 g.kg-1.24 hr-1, N = 14
Study: 7591421
Drug: Simple silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple silicone gel sheets
Study: 7427409
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg daily for three weeks) with Propranolol
Study: 7427409
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg daily for three weeks) with Thiazide diuretics
Study: 7427409
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with Thiazide diuretics
Study: 30803290
Drug: Intraoperative plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative plus postoperative hemoadsorption therapy
Study: 30803290
Drug: Sole intraoperative
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole intraoperative hemoadsorption therapy
Study: 29280118
Drug: Microecological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microecological treatment group
Study: 25902320
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 ng•mL with propofol TCI between 2.40 and 4.23 μg•mL (bolus of 1 mg•kg)
Study: 25902320
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 ng•mL with propofol TCI between 2.15 and 2.88 μg•mL (bolus of 0.75 mg•kg)
Study: 25902320
Drug: Propofol fixed
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol fixed at 2 μg•mL with remifentanil TCI between 1.00 to 4.79 ng•mL
Study: 25902320
Drug: Propofol fixed
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol fixed at 3 μg•mL with remifentanil TCI between 0.72 to 3.19 ng•mL
Study: 21131862
Drug: One-third maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-third maintenance dose of resistance training
Study: 21131862
Drug: One-ninth maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-ninth maintenance dose of resistance training
Study: 19750261
Drug: Aspirin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1.5 g/day, 500 mg every 8 hours)
Study: 19799843
Drug: Virosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal vaccine
Study: 12553505
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg meloxicam
Study: 29476542
Drug: Emollient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient treatment (specific emollients not detailed)
Study: 12055813
Drug: Nitazoxanide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (100 mg for age 1-3 years or 200 mg for age 4-11 years, twice daily for 3 days)
Study: 12055813
Drug: Praziquantel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (25 mg/kg single dose)
Study: 10480704
Drug: Non-fasting serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fasting serum true insulin concentration
Study: 10480704
Drug: Non-fasting serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fasting serum glucose > or =6.1 mmol/l at baseline
Study: 8983443
Drug: D‐dimer level
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐dimer level detected using semiquantitative method (D‐dimer Latex Test, Diagnostica Stago‐Boehringer Mannheim) before and during treatment.
Study: 8983443
Drug: Cells number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cells number and composition using light microscope before and during treatment.
Study: 8983443
Drug: D‐dimer level
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐dimer level in tuberculous effusions before treatment.
Study: 1765040
Drug: Moderate-dose fentanyl
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose fentanyl (20 micrograms kg-1) combined with isoflurane, nitrous oxide and oxygen
Study: 6604371
Drug: Neodymium-Yag laser
Normalized name: Neodymium
DrugBank: Neodymium (DB15318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neodymium-Yag laser treatment
Study: 22769569
Drug: UFT adjuvant
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT adjuvant therapy (500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by 2-day rest, repeated for 1 year)
Study: 22769569
Drug: UFT adjuvant
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT adjuvant therapy
Study: 22769569
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without any adjuvant treatment
Study: 15933481
Drug: Long-acting risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting risperidone (25, 50 or 75 mg every 2 weeks)
Study: 8783991
Drug: Aprotinin (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (full recommended dose) in group D
Study: 1474275
Drug: BCG 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.1 mg + 6 x 10(8) KML (I)
Study: 1474275
Drug: BCG 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.1 mg + 5 x 10(7) KML (II)
Study: 1474275
Drug: BCG 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.1 mg + 5 x 10(6) KML (III)
Study: 1474275
Drug: BCG 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.1 mg (IV)
Study: 6204413
Drug: Control (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (3 mg/kg heparin)
Study: 6204413
Drug: Prostacyclin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin infusion before CPB
Study: 24825343
Drug: Pre-dialysis heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-dialysis heparin coating of the membrane
Study: 24825343
Drug: Constant saline
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant saline infusion
Study: 21105281
Drug: Risperidone at
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone at 6 mg/d plus buspirone at 60 mg/d
Study: 21105281
Drug: Risperidone at
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone at 6 mg/d plus placebo
Study: 12842375
Drug: Oral opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral opioid analgesia
Study: 10658520
Drug: Carboplatin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (200 mg/m2) and cisplatin (60 mg/m2) with ifosfamide
Study: 10658520
Drug: Carboplatin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (200 mg/m2) and cisplatin (60 mg/m2) without ifosfamide
Study: 6652010
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg i.m.
Study: 8889289
Drug: ACET/COD combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACET/COD combination
Study: 3330115
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg tid)
Study: 6209500
Drug: Metformin (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (after placebo)
Study: 6209500
Drug: Metformin (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (during treatment)
Study: 31603076
Drug: Transcutaneous Vagal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous Vagal Nerve Stimulation (t-VNS) using GammaCore device for 2 weeks, self-administered three times per day.
Study: 31603076
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for 2 weeks, self-administered three times per day.
Study: 28852716
Drug: Dry cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry cupping therapy on the abdominal wall for 8 minutes every other day for 4 weeks
Study: 28852716
Drug: Standard laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard laxative therapy (Polyethylene glycol (PEG) 40% solution without electrolyte), 0.4 g/kg once daily for 4 weeks
Study: 28852716
Drug: Standard laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard laxative therapy
Study: 17623805
Drug: meat-sweet dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: meat-sweet dietary pattern (4th quartile) in postmenopausal women with estrogen receptor-positive tumors
Study: 8513736
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (1.5 mmols and above)
Study: 23608794
Drug: Golden Bifid
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golden Bifid 2.0 g, bid for 24 months
Study: 23608794
Drug: Changmei 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changmei 1.0 g, tid for 24 months
Study: 23608794
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Golden Bifid and Changmei for 24 months
Study: 15204012
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg xaliproden
Study: 9824789
Drug: piperacillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin (4 g) plus ciprofloxacin (400 mg)
Study: 9824789
Drug: piperacillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin (4 g) plus tazobactam (0.5 g)
Study: 9824789
Drug: piperacillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin (4 g)
Study: 9824789
Drug: ciprofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin (400 mg)
Study: 25812179
Drug: Increased oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased oral lingual pressure during swallowing
Study: 21907600
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg · day(‐1))
Study: 21907600
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (650 mg · day(‐1))
Study: 21907600
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose capsule)
Study: 19184028
Drug: Raj yoga
Normalized name: drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Raj yoga program (bi-weekly for 12 sessions)
Study: 15978307
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 25 mg
Study: 11327442
Drug: Zidovudine plus
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine plus zalcitabine (200 mg zidovudine three times daily + 0.75 mg zalcitabine three times daily)
Study: 11327442
Drug: Zidovudine monotherapy
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine monotherapy (200 mg three times daily)
Study: 8434265
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education message and antimalarial drug intervention 1
Study: 8434265
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education message and antimalarial drug intervention 2
Study: 8434265
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education message and antimalarial drug intervention 3
Study: 3315267
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A - 8 mg/kg at 0700 hr and 4 mg/kg at 1900 hr
Study: 3315267
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B - 6 mg/kg at 0700 hr and 6 mg/kg at 1900 hr
Study: 3315267
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C - 4 mg/kg at 0700 hr and 8 mg/kg at 1900 hr
Study: 30917809
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without bleaching treatment
Study: 28272596
Drug: Pharmacists obtaining
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists obtaining admission medication histories (AMHs)
Study: 24485339
Drug: 5% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sucrose solution
Study: 24485339
Drug: Aspartate solution
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartate solution
Study: 24485339
Drug: Cortisol levels
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol levels after all treatments (sucrose, aspartate, placebo)
Study: 15486840
Drug: Conventional report
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional report + written alert + oral clinical advice (Group C)
Study: 20350251
Drug: Alpha-tocopherol 50
Normalized name: (+)-alpha-tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol 50 mg/day
Study: 20350251
Drug: Beta-carotene 20
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene 20 mg/day
Study: 7931205
Drug: Desipramine blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine blood levels above 123 ng/ml at week 2
Study: 3203062
Drug: Inhaled PAF
Normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled PAF
Study: 19040036
Drug: Healive (inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healive (inactivated hepatitis A vaccine)
Study: 12866325
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aqueous (TAA AQ) 200 micrograms once daily (n = 75)
Study: 12866325
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous (BDP) 336 micrograms twice daily (n = 77)
Study: 10783825
Drug: Erythromycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (2 g)
Study: 6743479
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg once‐daily)
Study: 3534594
Drug: Additional chemotherapy
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional chemotherapy with alternate drugs after completion of FAC
Study: 26637514
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.4 mg/m² as a two‐ to five‐minute i.v. infusion on days 1 and 8 of a 21‐day cycle
Study: 24189290
Drug: CapOpus (motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapOpus (motivational interviewing and cognitive behavior therapy)
Study: 16798652
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of deferiprone (L1) daily plus desferrioxamine (DFO) twice weekly
Study: 19456797
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate 0.1% cream
Study: 11273943
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg hyperbaric tetracaine
Study: 11273943
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg hyperbaric tetracaine, 10 microg fentanyl, and 0.2 mg epinephrine
Study: 11273943
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg hyperbaric tetracaine, 10 microg fentanyl, and 0.2 mL saline
Study: 8387662
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg (pretreatment)
Study: 3475987
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose droperidol (0.25 mg)
Study: 3475987
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose droperidol (0.5 mg)
Study: 21402650
Drug: Basic Body
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic Body Awareness Therapy for seven weeks
Study: 14733349
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave treatments (ESW)
Study: 10657406
Drug: GV150526 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV150526 (800 mg loading dose followed by 200 mg every 12 hours for 3 days)
Study: 8422658
Drug: Oral physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physostigmine (OP) 16 mg/day for 6 weeks
Study: 3020227
Drug: Pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10 mg q.i.d.)
Study: 3020227
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg q.i.d.)
Study: 27289163
Drug: Meal containing
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal containing 10 g of extra virgin olive oil (EVOO)
Study: 25281778
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin daily
Study: 21499206
Drug: Secretin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secretin (16 μg administered intravenously before ERCP)
Study: 17293736
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator therapy in patients with NYHA class II HF
Study: 17293736
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator therapy in patients with NYHA class III HF
Study: 17293736
Drug: Amiodarone drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone drug therapy in patients with NYHA class III HF
Study: 15228214
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of beta‐conglycinin (5 g daily)
Study: 7870963
Drug: Active gum
Normalized name: STANNOUS FLUORIDE 1.1 mg in 1 g DENTAL PASTE [parodontax Active Gum Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active gum + active patch (double active)
Study: 7870963
Drug: Active gum
Normalized name: STANNOUS FLUORIDE 1.1 mg in 1 g DENTAL PASTE [parodontax Active Gum Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active gum + placebo patch (gum only active)
Study: 7870963
Drug: Placebo gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gum + active patch (patch active)
Study: 7870963
Drug: Placebo gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gum + placebo patch (double placebo)
Study: 30541604
Drug: Thread-embedding acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thread-embedding acupuncture (TEA), administered once every 2 weeks for 8 weeks (4 sessions total)
Study: 30541604
Drug: Acupuncture, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, administered twice per week for 8 weeks (16 sessions total)
Study: 22078221
Drug: Fibrinolysis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis treatment in women
Study: 22078221
Drug: Fibrinolysis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis treatment in men
Study: 22078221
Drug: Fibrinolysis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis treatment in women with bleeding
Study: 22078221
Drug: Fibrinolysis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis treatment in men with bleeding
Study: 22078221
Drug: Fibrinolysis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis treatment in women without bleeding
Study: 22078221
Drug: Fibrinolysis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis treatment in men without bleeding
Study: 19852962
Drug: TMC435 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 200 mg once daily for 5 days (patients)
Study: 19852962
Drug: TMC435 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 (various doses) in healthy volunteers
Study: 19852962
Drug: TMC435 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 200 mg twice daily or 100, 200, or 400 mg once daily (healthy volunteers)
Study: 17038828
Drug: Respiratory route
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory route of measles vaccine administration